Novel RNA interference-based therapies for sepsis

Bibliography

• Lever A, Mackenzie I. Sepsis: definition, epidemiology, and diagnosis. BMJ 2007;335(7625):879-83
   PubMed Web of Science ®Google Scholar
• Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell 2006;124(4):783-801
   PubMed Web of Science ®Google Scholar
• Jean-Baptiste E. Cellular mechanisms in sepsis. J Intensive Care Med 2007;22(2):63-72
   PubMedGoogle Scholar
• Buras JA, Holzmann B, Sitkovsky M. Animal models of sepsis: setting the stage. Nat Rev Drug Discov 2005;4(10):854-65
   PubMed Web of Science ®Google Scholar
• Thomas L. Germs. N Engl J Med 1972;287(11):553-5
   PubMed Web of Science ®Google Scholar
• Gogos CA, Drosou E, Bassaris HP, Skoutelis A. Pro- versus anti-inflammatory cytokine profile in patients with severe sepsis: a marker for prognosis and future therapeutic options. J Infect Dis 2000;181(1):176-80
   PubMed Web of Science ®Google Scholar
• Munford RS, Pugin J. Normal responses to injury prevent systemic inflammation and can be immunosuppressive. Am J Respir Crit Care Med 2001;163(2):316-21
   PubMed Web of Science ®Google Scholar
• Hotchkiss RS, Karl IE. The pathophysiology and treatment of sepsis. N Engl J Med 2003;348(2):138-50
   PubMed Web of Science ®Google Scholar
• Zhang Q, Raoof M, Chen Y, et al. Circulating mitochondrial DAMPs cause inflammatory responses to injury. Nature 2010;464(7285):104-7
   PubMed Web of Science ®Google Scholar
• Namas R, Ghuma A, Hermus L, et al. The acute inflammatory response in trauma/hemorrhage and traumatic brain injury: current state and emerging prospects. Libyan J Med 2009;4(3):97-103
   Web of Science ®Google Scholar
• Ciriello V, Gudipati S, Stavrou PZ, et al. Biomarkers predicting sepsis in polytrauma patients: current evidence. Injury 2013;44(12):1680-92
   PubMed Web of Science ®Google Scholar
• Bone RC. Immunologic dissonance: a continuing evolution in our understanding of the systemic inflammatory response syndrome (SIRS) and the multiple organ dysfunction syndrome (MODS). Ann Intern Med 1996;125(8):680-7
   PubMed Web of Science ®Google Scholar
• Pinsky MR, Vincent JL, Deviere J, et al. Serum cytokine levels in human septic shock. Relation to multiple-system organ failure and mortality. Chest 1993;103(2):565-75
   PubMed Web of Science ®Google Scholar
• Friedman G, Jankowski S, Marchant A, et al. Blood interleukin 10 levels parallel the severity of septic shock. J Crit Care 1997;12(4):183-7
   PubMed Web of Science ®Google Scholar
• Waage A, Halstensen A, Espevik T. Association between tumour necrosis factor in serum and fatal outcome in patients with meningococcal disease. Lancet 1987;1(8529):355-7
   PubMed Web of Science ®Google Scholar
• Girardin E, Grau GE, Dayer JM, et al. Tumor necrosis factor and interleukin-1 in the serum of children with severe infectious purpura. N Engl J Med 1988;319(7):397-400
   PubMed Web of Science ®Google Scholar
• Damas P, Ledoux D, Nys M, et al. Cytokine serum level during severe sepsis in human IL-6 as a marker of severity. Ann Surg 1992;215(4):356-62
   PubMed Web of Science ®Google Scholar
• Lehmann AK, Halstensen A, Sørnes S, et al. High levels of interleukin 10 in serum are associated with fatality in meningococcal disease. Infect Immun 1995;63(6):2109-12
   PubMed Web of Science ®Google Scholar
• Hazelzet JA, Kornelisse RF, van der Pouw Kraan TC, et al. Interleukin 12 levels during the initial phase of septic shock with purpura in children: relation to severity of disease. Cytokine 1997;9(9):711-16
   PubMed Web of Science ®Google Scholar
• Kasai T, Inada K, Takakuwa T, et al. Anti-inflammatory cytokine levels in patients with septic shock. Res Commun Mol Pathol Pharmacol 1997;98(1):34-42
   PubMed Web of Science ®Google Scholar
• van der Poll T, de Waal Malefyt R, Coyle SM, Lowry SF. Antiinflammatory cytokine responses during clinical sepsis and experimental endotoxemia: sequential measurements of plasma soluble interleukin (IL)-1 receptor type II, IL-10, and IL-13. J Infect Dis 1997;175(1):118-22
   PubMed Web of Science ®Google Scholar
• Brealey D, Brand M, Hargreaves I, et al. Association between mitochondrial dysfunction and severity and outcome of septic shock. Lancet 2002;360(9328):219-23
   PubMed Web of Science ®Google Scholar
• Castellheim A, Brekke OL, Espevik T, et al. Innate immune responses to danger signals in systemic inflammatory response syndrome and sepsis. Scand J Immunol 2009;69(6):479-91
   PubMed Web of Science ®Google Scholar
• Carre JE, Singer M. Cellular energetic metabolism in sepsis: the need for a systems approach. Biochim Biophys Acta 2008;1777(7-8):763-71
   PubMed Web of Science ®Google Scholar
• Levy RJ, Deutschman CS. Cytochrome c oxidase dysfunction in sepsis. Crit Care Med 2007;35(9 Suppl):S468-75
   PubMed Web of Science ®Google Scholar
• Hotchkiss RS, Tinsley KW, Swanson PE, Karl IE. Endothelial cell apoptosis in sepsis. Crit Care Med 2002;30(5 Suppl):S225-8
   PubMed Web of Science ®Google Scholar
• Hotchkiss RS, Coopersmith CM, Karl IE. Prevention of lymphocyte apoptosis–a potential treatment of sepsis? Clin Infect Dis 2005;41(Suppl 7):S465-9
   PubMedGoogle Scholar
• Tribl B, Sibbald WJ, Vogelsang H, et al. Exocrine pancreatic dysfunction in sepsis. Eur J Clin Invest 2003;33(3):239-43
   PubMed Web of Science ®Google Scholar
• Fire A, Xu S, Montgomery MK, et al. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 1998;391(6669):806-11
   PubMed Web of Science ®Google Scholar
• Manoharan M. RNA interference and chemically modified small interfering RNAs. Curr Opin Chem Biol 2004;8(6):570-9
   PubMed Web of Science ®Google Scholar
• Juliano RL, Ming X, Nakagawa O. The chemistry and biology of oligonucleotide conjugates. Acc Chem Res 2012;45(7):1067-76
   PubMed Web of Science ®Google Scholar
• Whitehead KA, Langer R, Anderson DG. Knocking down barriers: advances in siRNA delivery. Nat Rev Drug Discov 2009;8(2):129-38
   PubMed Web of Science ®Google Scholar
• Stevenson M. Therapeutic potential of RNA interference. N Engl J Med 2004;351(17):1772-7
   PubMed Web of Science ®Google Scholar
• Leonard JN, Schaffer DV. Antiviral RNAi therapy: emerging approaches for hitting a moving target. Gene Ther 2006;13(6):532-40
   PubMed Web of Science ®Google Scholar
• Ellisen LW, Ramsayer KD, Johannessen CM, et al. REDD1, a developmentally regulated transcriptional target of p63 and p53, links p63 to regulation of reactive oxygen species. Mol Cell 2002;10(5):995-1005
   PubMed Web of Science ®Google Scholar
• Shoshani T, Faerman A, Mett I, et al. Identification of a novel hypoxia-inducible factor 1-responsive gene, RTP801, involved in apoptosis. Mol Cell Biol 2002;22(7):2283-93
   PubMed Web of Science ®Google Scholar
• Wang Z, Malone MH, Thomenius MJ, et al. Dexamethasone-induced gene 2 (dig2) is a novel pro-survival stress gene induced rapidly by diverse apoptotic signals. J Biol Chem 2003;278(29):27053-8
   PubMed Web of Science ®Google Scholar
• Lee DU, Huang W, Rittenhouse KD, Jessen B. Retina expression and cross-species validation of gene silencing by PF-655, a small interfering RNA against RTP801 for the treatment of ocular disease. J Ocul Pharmacol Ther 2012;28(3):222-30
   PubMed Web of Science ®Google Scholar
• DeVincenzo J, Lambkin-Williams R, Wilkinson T, et al. A randomized, double-blind, placebo-controlled study of an RNAi-based therapy directed against respiratory syncytial virus. Proc Natl Acad Sci USA 2010;107(19):8800-5
   PubMed Web of Science ®Google Scholar
• Aagaard L, Rossi JJ. RNAi therapeutics: principles, prospects and challenges. Adv Drug Deliv Rev 2007;59(2-3):75-86
   PubMed Web of Science ®Google Scholar
• Fedorov Y, Anderson EM, Birmingham A, et al. Off-target effects by siRNA can induce toxic phenotype. RNA 2006;12(7):1188-96
   PubMed Web of Science ®Google Scholar
• Jackson AL, Burchard J, Schelter J, et al. Widespread siRNA “off-target” transcript silencing mediated by seed region sequence complementarity. RNA 2006;12(7):1179-87
   PubMed Web of Science ®Google Scholar
• Caffrey DR, Zhao J, Song Z, et al. siRNA off-target effects can be reduced at concentrations that match their individual potency. PLoS One 2011;6(7):e21503
   PubMed Web of Science ®Google Scholar
• Akinc A, Querbes W, De S, et al. Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms. Mol Ther 2010;18(7):1357-64
   PubMed Web of Science ®Google Scholar
• de Fougerolles AR. Delivery vehicles for small interfering RNA in vivo. Hum Gene Ther 2008;19(2):125-32
   PubMed Web of Science ®Google Scholar
• Zimmermann TS, Lee AC, Akinc A, et al. RNAi-mediated gene silencing in non-human primates. Nature 2006;441(7089):111-14
   PubMed Web of Science ®Google Scholar
• Gao K, Huang L. Nonviral methods for siRNA delivery. Mol Pharm 2009;6(3):651-8
   PubMedGoogle Scholar
• Aouadi M, Tesz GJ, Nicoloro SM, et al. Orally delivered siRNA targeting macrophage Map4k4 suppresses systemic inflammation. Nature 2009;458(7242):1180-4
   PubMed Web of Science ®Google Scholar
• Park K, Yang JA, Lee MY, et al. Reducible hyaluronic acid-siRNA conjugate for target specific gene silencing. Bioconjug Chem 2013;24(7):1201-9
   PubMed Web of Science ®Google Scholar
• Howard KA, Paludan SR, Behlke MA, et al. Chitosan/siRNA nanoparticle-mediated TNF-alpha knockdown in peritoneal macrophages for anti-inflammatory treatment in a murine arthritis model. Mol Ther 2009;17(1):162-8
   PubMed Web of Science ®Google Scholar
• Lee JB, Hong J, Bonner DK, et al. Self-assembled RNA interference microsponges for efficient siRNA delivery. Nat Mater 2012;11(4):316-22
   PubMed Web of Science ®Google Scholar
• Musacchio T, Vaze O, D'Souza G, Torchilin VP. Effective stabilization and delivery of siRNA: reversible siRNA-phospholipid conjugate in nanosized mixed polymeric micelles. Bioconjug Chem 2010;21(8):1530-6
   PubMed Web of Science ®Google Scholar
• Jeong JH, Mok H, Oh YK, Park TG. siRNA conjugate delivery systems. Bioconjug Chem 2009;20(1):5-14
   PubMed Web of Science ®Google Scholar
• Soutschek J, Akinc A, Bramlage B, et al. Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature 2004;432(7014):173-8
   PubMed Web of Science ®Google Scholar
• Severgnini M, Sherman J, Sehgal A, et al. A rapid two-step method for isolation of functional primary mouse hepatocytes: cell characterization and asialoglycoprotein receptor based assay development. Cytotechnology 2012;64(2):187-95
   PubMed Web of Science ®Google Scholar
• Khorev O, Stokmaier D, Schwardt O, et al. Trivalent, Gal/GalNAc-containing ligands designed for the asialoglycoprotein receptor. Bioorg Med Chem 2008;16(9):5216-31
   PubMed Web of Science ®Google Scholar
• Wooddell CI, Rozema DB, Hossbach M, et al. Hepatocyte-targeted RNAi therapeutics for the treatment of chronic hepatitis B virus infection. Mol Ther 2013;21(5):973-85
   PubMed Web of Science ®Google Scholar
• Parmar RG, Busuek M, Walsh ES, et al. Endosomolytic bioreducible poly(amido amine disulfide) polymer conjugates for the in vivo systemic delivery of siRNA therapeutics. Bioconjug Chem 2013;24(4):640-7
   PubMed Web of Science ®Google Scholar
• Nishina K, Unno T, Uno Y, et al. Efficient in vivo delivery of siRNA to the liver by conjugation of alpha-tocopherol. Mol Ther 2008;16(4):734-40
   PubMed Web of Science ®Google Scholar
• Mok H, Lee SH, Park JW, Park TG. Multimeric small interfering ribonucleic acid for highly efficient sequence-specific gene silencing. Nat Mater 2010;9(3):272-8
   PubMed Web of Science ®Google Scholar
• Sahoo SK, Labhasetwar V. Nanotech approaches to drug delivery and imaging. Drug Discov Today 2003;8(24):1112-20
   PubMed Web of Science ®Google Scholar
• Kim SS, Ye C, Kumar P, et al. Targeted delivery of siRNA to macrophages for anti-inflammatory treatment. Mol Ther 2010;18(5):993-1001
   PubMed Web of Science ®Google Scholar
• Leuschner F, Dutta P, Gorbatov R, et al. Therapeutic siRNA silencing in inflammatory monocytes in mice. Nat Biotechnol 2011;29(11):1005-10
   PubMed Web of Science ®Google Scholar
• Novobrantseva TI, Borodovsky A, Wong J, et al. Systemic RNAi-mediated gene silencing in nonhuman primate and rodent myeloid cells. Mol Ther Nucleic Acids 2012;1:e4
   PubMedGoogle Scholar
• Jain S, Amiji M. Tuftsin-modified alginate nanoparticles as a noncondensing macrophage-targeted DNA delivery system. Biomacromolecules 2012;13(4):1074-85
   PubMed Web of Science ®Google Scholar
• Kortylewski M, Swiderski P, Herrmann A, et al. In vivo delivery of siRNA to immune cells by conjugation to a TLR9 agonist enhances antitumor immune responses. Nat Biotechnol 2009;27(10):925-32
   PubMed Web of Science ®Google Scholar
• Kumar P, Ban HS, Kim SS, et al. T cell-specific siRNA delivery suppresses HIV-1 infection in humanized mice. Cell 2008;134(4):577-86
   PubMed Web of Science ®Google Scholar
• Qin XF, An DS, Chen IS, Baltimore D. Inhibiting HIV-1 infection in human T cells by lentiviral-mediated delivery of small interfering RNA against CCR5. Proc Natl Acad Sci USA 2003;100(1):183-8
   PubMed Web of Science ®Google Scholar
• Peer D, Park EJ, Morishita Y. Systemic leukocyte-directed siRNA delivery revealing cyclin D1 as an anti-inflammatory target. Science 2008;319(5863):627-30
   PubMed Web of Science ®Google Scholar
• Whitehead KA, Dahlman JE, Langer RS, Anderson DG. Silencing or stimulation? siRNA delivery and the immune system. Annu Rev Chem Biomol Eng 2011;2:77-96
   PubMed Web of Science ®Google Scholar
• Robbins M, Judge A, Ambegia E. Misinterpreting the therapeutic effects of small interfering RNA caused by immune stimulation. Hum Gene Ther 2008;19(10):991-9
   PubMed Web of Science ®Google Scholar
• Basha G, Novobrantseva TI, Rosin N, et al. Influence of cationic lipid composition on gene silencing properties of lipid nanoparticle formulations of siRNA in antigen-presenting cells. Mol Ther 2011;19(12):2186-200
   PubMed Web of Science ®Google Scholar
• Li R, Zheng X, Popov I, et al. Gene silencing of IL-12 in dendritic cells inhibits autoimmune arthritis. J Transl Med 2012;10:19
   PubMed Web of Science ®Google Scholar
• Ranjha R, Paul J. Micro-RNAs in inflammatory diseases and as a link between inflammation and cancer. Inflamm Res 2013;62(4):343-55
   PubMed Web of Science ®Google Scholar
• Hawkins PG, Morris KV. RNA and transcriptional modulation of gene expression. Cell Cycle 2008;7(5):602-7
   PubMed Web of Science ®Google Scholar
• Nana-Sinkam SP, Karsies T, Riscili B, et al. Lung microRNA: from development to disease. Expert Rev Respir Med 2009;3(4):373-85
   PubMedGoogle Scholar
• Poy MN, Eliasson L, Krutzfeldt J, et al. A pancreatic islet-specific microRNA regulates insulin secretion. Nature 2004;432(7014):226-30
   PubMed Web of Science ®Google Scholar
• Sonkoly E, Janson P, Majuri ML, et al. MiR-155 is overexpressed in patients with atopic dermatitis and modulates T-cell proliferative responses by targeting cytotoxic T lymphocyte-associated antigen 4. J Allergy Clin Immunol 2010;126(3):581-9.e1-20.
   PubMed Web of Science ®Google Scholar
• Harris TA, Yamakuchi M, Kondo M, et al. Ets-1 and Ets-2 regulate the expression of microRNA-126 in endothelial cells. Arterioscler Thromb Vasc Biol 2010;30(10):1990-7
   PubMed Web of Science ®Google Scholar
• Fasseu M, Tréton X, Guichard C, et al. Identification of restricted subsets of mature microRNA abnormally expressed in inactive colonic mucosa of patients with inflammatory bowel disease. PLoS One 2010;5(10):e13160
   PubMed Web of Science ®Google Scholar
• Pauley KM, Cha S. miRNA-146a in rheumatoid arthritis: a new therapeutic strategy. Immunotherapy 2011;3(7):829-31
   PubMed Web of Science ®Google Scholar
• Wang L, Wang HC, Chen C, et al. Differential expression of plasma miR-146a in sepsis patients compared with non-sepsis-SIRS patients. Exp Ther Med 2013;5(4):1101-4
   PubMed Web of Science ®Google Scholar
• Taganov KD, Boldin MP, Chang KJ, Baltimore D. NF-kappaB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. Proc Natl Acad Sci USA 2006;103(33):12481-6
   PubMed Web of Science ®Google Scholar
• Cortez MA, Calin GA. MicroRNA identification in plasma and serum: a new tool to diagnose and monitor diseases. Expert Opin Biol Ther 2009;9(6):703-11
   PubMed Web of Science ®Google Scholar
• Wang JF, Yu ML, Yu G, et al. Serum miR-146a and miR-223 as potential new biomarkers for sepsis. Biochem Biophys Res Commun 2010;394(1):184-8
   PubMed Web of Science ®Google Scholar
• Li T, Morgan MJ, Choksi S, et al. MicroRNAs modulate the noncanonical transcription factor NF-kappaB pathway by regulating expression of the kinase IKKalpha during macrophage differentiation. Nat Immunol 2010;11(9):799-805
   PubMed Web of Science ®Google Scholar
• Chen Q, Wang H, Liu Y, et al. Inducible microRNA-223 down-regulation promotes TLR-triggered IL-6 and IL-1beta production in macrophages by targeting STAT3. PLoS One 2012;7(8):e42971
   PubMed Web of Science ®Google Scholar
• Nahid MA, Satoh M, Chan EK. Mechanistic role of microRNA-146a in endotoxin-induced differential cross-regulation of TLR signaling. J Immunol 2011;186(3):1723-34
   PubMed Web of Science ®Google Scholar
• Brahmamdam P, Watanabe E, Unsinger J, et al. Targeted delivery of siRNA to cell death proteins in sepsis. Shock 2009;32(2):131-9
   PubMed Web of Science ®Google Scholar
• Hotchkiss RS, Chang KC, Swanson PE, et al. Caspase inhibitors improve survival in sepsis: a critical role of the lymphocyte. Nat Immunol 2000;1(6):496-501
   PubMed Web of Science ®Google Scholar
• Schwulst SJ, Muenzer JT, Peck-Palmer OM, et al. Bim siRNA decreases lymphocyte apoptosis and improves survival in sepsis. Shock 2008;30(2):127-34
   PubMed Web of Science ®Google Scholar
• Osuchowski MF, Welch K, Siddiqui J, Remick DG. Circulating cytokine/inhibitor profiles reshape the understanding of the SIRS/CARS continuum in sepsis and predict mortality. J Immunol 2006;177(3):1967-74
   PubMed Web of Science ®Google Scholar
• Reinhart K, Karzai W. Anti-tumor necrosis factor therapy in sepsis: update on clinical trials and lessons learned. Crit Care Med 2001;29(7 Suppl):S121-5
   PubMed Web of Science ®Google Scholar
• Casey LC, Balk RA, Bone RC. Plasma cytokine and endotoxin levels correlate with survival in patients with the sepsis syndrome. Ann Intern Med 1993;119(8):771-8
   PubMed Web of Science ®Google Scholar
• Debets JM, Kampmeijer R, van der Linden MP, et al. Plasma tumor necrosis factor and mortality in critically ill septic patients. Crit Care Med 1989;17(6):489-94
   PubMed Web of Science ®Google Scholar
• Dofferhoff AS, Bom VJ, de Vries-Hospers HG, et al. Patterns of cytokines, plasma endotoxin, plasminogen activator inhibitor, and acute-phase proteins during the treatment of severe sepsis in humans. Crit Care Med 1992;20(2):185-92
   PubMed Web of Science ®Google Scholar
• Marshall JC. Such stuff as dreams are made on: mediator-directed therapy in sepsis. Nat Rev Drug Discov 2003;2(5):391-405
   PubMed Web of Science ®Google Scholar
• Fisher CJ Jr, Agosti JM, Opal SM, et al. Treatment of septic shock with the tumor necrosis factor receptor:fc fusion protein. The Soluble TNF receptor Sepsis Study Group. N Engl J Med 1996;334(26):1697-702
   PubMed Web of Science ®Google Scholar
• Abraham E, Glauser MP, Butler T, et al. p55 Tumor necrosis factor receptor fusion protein in the treatment of patients with severe sepsis and septic shock. A randomized controlled multicenter trial. Ro 45-2081 Study Group. JAMA 1997;277(19):1531-8
   PubMed Web of Science ®Google Scholar
• Abraham E, Laterre PF, Garbino J, et al. Lenercept (p55 tumor necrosis factor receptor fusion protein) in severe sepsis and early septic shock: a randomized, double-blind, placebo-controlled, multicenter phase III trial with 1,342 patients. Crit Care Med 2001;29(3):503-10
   PubMed Web of Science ®Google Scholar
• Sorensen DR, Leirdal M, Sioud M. Gene silencing by systemic delivery of synthetic siRNAs in adult mice. J Mol Biol 2003;327(4):761-6
   PubMed Web of Science ®Google Scholar
• Rice TW, Bernard GR. Therapeutic intervention and targets for sepsis. Annu Rev Med 2005;56:225-48
   PubMed Web of Science ®Google Scholar
• Gibot S, Massin F, Marcou M, et al. TREM-1 promotes survival during septic shock in mice. Eur J Immunol 2007;37(2):456-66
   PubMed Web of Science ®Google Scholar
• Furset G, Sioud M. Design of bifunctional siRNAs: combining immunostimulation and gene-silencing in one single siRNA molecule. Biochem Biophys Res Commun 2007;352(3):642-9
   PubMed Web of Science ®Google Scholar
• Blackwell TS, Christman JW. Sepsis and cytokines: current status. Br J Anaesth 1996;77(1):110-17
   PubMed Web of Science ®Google Scholar
• Riedemann NC, Neff TA, Guo RF, et al. Protective effects of IL-6 blockade in sepsis are linked to reduced C5a receptor expression. J Immunol 2003;170(1):503-7
   PubMed Web of Science ®Google Scholar
• Panacek EA, Marshall JC, Albertson TE, et al. Efficacy and safety of the monoclonal anti-tumor necrosis factor antibody F(ab')2 fragment afelimomab in patients with severe sepsis and elevated interleukin-6 levels. Crit Care Med 2004;32(11):2173-82
   PubMed Web of Science ®Google Scholar
• Mostafa Anower AK, Shim JA, Choi B, Sohn S. Pretreatment with interleukin-6 small interfering RNA can improve the survival rate of polymicrobial cecal ligation and puncture mice by down regulating interleukin-6 production. Eur J Pharmacol 2012;688(1-3):76-83
   PubMed Web of Science ®Google Scholar
• Lomas-Neira JL, Chung CS, Wesche DE, et al. In vivo gene silencing (with siRNA) of pulmonary expression of MIP-2 versus KC results in divergent effects on hemorrhage-induced, neutrophil-mediated septic acute lung injury. J Leukoc Biol 2005;77(6):846-53
   PubMed Web of Science ®Google Scholar
• Bommhardt U, Chang KC, Swanson PE, et al. Akt decreases lymphocyte apoptosis and improves survival in sepsis. J Immunol 2004;172(12):7583-91
   PubMed Web of Science ®Google Scholar
• Song GY, Chung CS, Chaudry IH, Ayala A. MAPK p38 antagonism as a novel method of inhibiting lymphoid immune suppression in polymicrobial sepsis. Am J Physiol Cell Physiol 2001;281(2):C662-9
   PubMed Web of Science ®Google Scholar